Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...
In RIP: Reincarnation Insurance Program we view the action from a bird's eye view. The title takes us to a world overrun by zombies, and during the gameplay we play the role of an agent whose task is ...
LawCrossing has introduced a newly updated comprehensive review database focused on BigLaw summer associate programs, providing law students and early-career professionals with a centralized resource ...
(RTTNews) - Organon (OGN) announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for NEXPLANON (etonogestrel implant). NEXPLANON is ...
The transfer portal is just warming ahead of its January 2nd official opening, but it's already busy in the Big Ten. While teams like James Madison and North Texas are suffering wholesale devastation, ...
CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...
MINOT — Recently I wrote about Thread, which for years was a start-up darling based in Grand Forks that was showered with state and federal tax dollars. The company, which is now in arrears on its ...
Frederick L. Locke, MD, discusses the 2025 removal of the REMS program for CAR T-cell therapy and the resulting improvements to patient access. Frederick L. Locke, MD, chair of the Department of Blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results